RxDoctor Payments Data

Mary Logan

Family · Reynoldsville, PANPI 1962917245

Payments from drug & device makers

$466in general payments, 2019–2025

Across 16 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$120
  • AbbVie$88
  • Smith+Nephew$75
  • Organogenesis Inc.$55
  • Stryker$41
  • Novo Nordisk$32
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$466100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$466 in reported general payments places this provider in the 55th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,851
Medicare patients
141
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$33,032
OzempicSemaglutide34$30,594
JanuviaSitagliptin Phosphate12$6,762
TradjentaLinagliptin14$6,491
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,658
Atorvastatin Calcium75$1,079
Metoprolol Succinate66$1,021
Albuterol Sulfate HfaAlbuterol Sulfate40$969
Gabapentin73$954
Pantoprazole Sodium66$885
Pioglitazone Hcl43$866
Losartan Potassium52$782
Levothyroxine Sodium68$769
Celecoxib17$752
Memantine Hcl ErMemantine Hcl12$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$30,59434 claims
AbbVieSynthroid$88$18311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,717 family providers in Pennsylvania.

Other family in Reynoldsville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →